351 related articles for article (PubMed ID: 17171557)
1. Agomelatine in the treatment of seasonal affective disorder.
Pjrek E; Winkler D; Konstantinidis A; Willeit M; Praschak-Rieder N; Kasper S
Psychopharmacology (Berl); 2007 Mar; 190(4):575-9. PubMed ID: 17171557
[TBL] [Abstract][Full Text] [Related]
2. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
[TBL] [Abstract][Full Text] [Related]
3. Agomelatine: efficacy at each phase of antidepressant treatment.
Kennedy SH
CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
[TBL] [Abstract][Full Text] [Related]
4. [A comparative evaluation of the efficacy of valdoxan (agomelatine) in recurrent depression and bipolar affective disorder].
Tiuvina NA; Smirnova VN
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(11 Pt 2):53-60. PubMed ID: 23257757
[TBL] [Abstract][Full Text] [Related]
5. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
Kasper S; Hamon M
World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
[TBL] [Abstract][Full Text] [Related]
6. Treating each and every depressed patient.
Kennedy SH
J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
[TBL] [Abstract][Full Text] [Related]
7. Addressing circadian rhythm disturbances in depressed patients.
Lam RW
J Psychopharmacol; 2008 Sep; 22(7 Suppl):13-8. PubMed ID: 18753278
[TBL] [Abstract][Full Text] [Related]
8. Agomelatine, an innovative pharmacological response to unmet needs.
Le Strat Y; Gorwood P
J Psychopharmacol; 2008 Sep; 22(7 Suppl):4-8. PubMed ID: 18753276
[TBL] [Abstract][Full Text] [Related]
9. Melatonin and agomelatine for preventing seasonal affective disorder.
Nussbaumer-Streit B; Greenblatt A; Kaminski-Hartenthaler A; Van Noord MG; Forneris CA; Morgan LC; Gaynes BN; Wipplinger J; Lux LJ; Winkler D; Gartlehner G
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD011271. PubMed ID: 31206585
[TBL] [Abstract][Full Text] [Related]
10. Agomelatine, a melatonin agonist with antidepressant properties.
Dubovsky SL; Warren C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
[TBL] [Abstract][Full Text] [Related]
11. Treatment of seasonal affective disorder with duloxetine: an open-label study.
Pjrek E; Willeit M; Praschak-Rieder N; Konstantinidis A; Semlitsch HV; Kasper S; Winkler D
Pharmacopsychiatry; 2008 May; 41(3):100-5. PubMed ID: 18484551
[TBL] [Abstract][Full Text] [Related]
12. Agomelatine: innovative pharmacological approach in depression.
Popoli M
CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
[TBL] [Abstract][Full Text] [Related]
13. Escitalopram in seasonal affective disorder: results of an open trial.
Pjrek E; Winkler D; Stastny J; Praschak-Rieder N; Willeit M; Kasper S
Pharmacopsychiatry; 2007 Jan; 40(1):20-4. PubMed ID: 17327956
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
[TBL] [Abstract][Full Text] [Related]
15. The mechanism, efficacy, and tolerability profile of agomelatine.
MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
[TBL] [Abstract][Full Text] [Related]
16. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.
Kennedy SH; Avedisova A; Giménez-Montesinos N; Belaïdi C; de Bodinat C;
Eur Neuropsychopharmacol; 2014 Apr; 24(4):553-63. PubMed ID: 24530273
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
Stein DJ; Ahokas AA; de Bodinat C
J Clin Psychopharmacol; 2008 Oct; 28(5):561-6. PubMed ID: 18794654
[TBL] [Abstract][Full Text] [Related]
18. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
Bourin M; Prica C
Curr Pharm Des; 2009; 15(14):1675-82. PubMed ID: 19442180
[TBL] [Abstract][Full Text] [Related]
19. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
San L; Arranz B
Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
[TBL] [Abstract][Full Text] [Related]
20. Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study.
Pardini M; Cordano C; Benassi F; Mattei C; Sassos D; Guida S; Serrati C; Primavera A; Amore M; Cocito L; Emberti Gialloreti L
Eur Neuropsychopharmacol; 2014 Jun; 24(6):939-44. PubMed ID: 24636462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
